June 2018

  TORONTO, June 27, 2018 — /D.M.O. Newswire/ —  Revive Therapeutics Ltd. (TSXV:RVV) (OTC:RVVTF) (FSE:31R) (“Revive” or the “Company”), a company focused on the research, development and commercialization of novel cannabinoid-based therapies, today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation for cannabidiol (“CBD”) in the treatment of autoimmune […]

Schedule 1 substances such as marijuana and heroin are considered to be the most deadly, and deemed to have no medical benefit at all. Epidiolex will be supplied as a 100mg/mL strawberry-flavored oral solution in 100mL bottles and is expected to be available for appropriate patients in Fall 2018. GW Pharmaceuticals makes the drug in […]

For thousands of years, cannabis has been used to treat everything from pain to indigestion. Now, it is finally making its pharmaceutical debut, potentially opening the door for further marijuana-based treatments. On Monday, the Food and Drug Administration announced the approval of Epidiolex, a cannabidiol (CBD) solution, to treat seizures in two rare forms of […]

Due to some interesting developments in health science, the future of the industrial hemp industry may be in the hands of the DEA once again. For the first time ever, the FDA approved a drug derived from marijuana. The active ingredient in Epidolex, which in clinical trials reduced the frequency of seizures in people with […]

515151 All that changed a year ago, when Benjamin started taking marijuana. In the little apartment he shares with his mother, mornings are now relaxed and orderly. His transformation may signal the arrival of a long-awaited and desperately needed healing for the many others just like him: children living with severe autism.

Other CBD-focused companies like Kalytera Therapeutics stand to benefit Kalytera is developing CBD for treatment prevention of graft-versus-host disease. The market for pharmaceutical products based on cannabidiol (“CBD”) got a big boost, courtesy of the U.S. Food Drug Administration. The FDA has approved GW Pharmaceuticals’ drug, Epidiolex, for the treatment of severe seizures in children […]

TORONTO, June 27, 2018 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (TSX VENTURE:RVV) (OTCQB:RVVTF) (FSE:31R) (“Revive” or the “Company”), a company focused on the research, development and commercialization of novel cannabinoid-based therapies, today announced that the U.S. Food and Drug Administration (“FDAâ€) has granted orphan drug designation for cannabidiol (“CBDâ€) in the treatment of autoimmune hepatitis […]

NEW YORK, June 28, 2018 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that the company will be attending as a sponsor. at the 28th Annual International Cannabinoid Research Society (ICRS) Symposium taking place in Leiden, The Netherlands from June 30 – July 5, […]

Revive Therapeutics Ltd (CVE:RVV) today released encouraging news that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for cannabidiol (CBD) in the treatment of autoimmune hepatitis (AIH) to Revive. This spells good news for the partnership between Revive and cannabis producer WeedMD Inc. (CVE:WMD). The two companies are looking at ways […]

Supreme Court Rules Against Unions in Mandatory Fees, and Anthony Kennedy Retires, by Bloomberg Microsoft Improves Biased Facial Recognition Technology, by Erin Corbett and Jonathan Vanian America’s Trucker Shortage Is Hitting Home, by Kirsten Korosec Find past coverage. Sign up for other Fortune newsletters. … read more at: http://fortune.com/2018/06/27/brainstorm-health-daily-06-27-18/

Save Article Revive Therapeutics Ltd. (TSXV:RVV), a cannabinoid biopharma stock, jumped after receiving an orphan drug designation for the treatment of autoimmune hepatitis Sean Mason | June 27, 2018 | SmallCapPower A U.S. Food and Drug Administration designation was good news for investors in a cannabinoid biopharma stock Wednesday. Here’s some small stocks making big moves on Wednesday, June […]